Alzamend Neuro Inc

ALZN • Biotechnology

$1.29

— 0.00 (0.00%)

ResultadosÚltimo reporte: 31 jul 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$5.78M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 1.31Rentabilidad débil

Datos financieros hasta: 31 jul 2026, 12:00 a.m. UTCÚltima actualización de earnings: 31 jul 2026, 12:00 a.m. UTCÚltima actualización del perfil: 11 sept 2026, 12:12 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.29

Change0.00%

Shares Out4.48M

Market Cap$5.78M

Enterprise Value$-1.81M

52W Range0.84 - 2.68

Beta0.19

P/E-0.64

P/B1.00

P/FCF-0.84

EV/EBITDA0.20

EV/FCF0.27

Price$1.29

Change0.00%

Shares Out4.48M

Market Cap$5.78M

Enterprise Value$-1.81M

52W Range0.84 - 2.68

Beta0.19

P/E-0.64

P/B1.00

P/FCF-0.84

EV/EBITDA0.20

EV/FCF0.27

Earnings Yield-157.45%

FCF Yield-118.45%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio1.31

Quick Ratio1.31

Volume8.71K

Avg Volume128.47K

EPS Surprise-0.05

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

84/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

60/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 1.31Rentabilidad débil

Analyst view

Analyst sentiment and price target

ALZN

Analyst sentiment

Based on 2 analyst votes · 2026-10-20

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 6/15/2021

Industria: Biotechnology

P/B i: 1.00

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje17 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 1.31

Ratio rápido: 1.31

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 1 venta interna de alto volumen detectada

AULT MILTON C III

Transacción: 08/26/2026

VENTA

Cambio

-2,000

Precio

$1.56

Presentación

08/31/2026

Tipo

VENTA

AULT MILTON C III

Transacción: 04/14/2026

COMPRA

Cambio

+2,000

Precio

$1.03

Presentación

08/31/2026

Tipo

COMPRA

AULT MILTON C III

Transacción: 07/31/2026

COMPRA

Cambio

+7,500

Precio

Not reported

Presentación

08/04/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
AULT MILTON C III	VENTA	-2,000	$1.56	08/26/2026	08/31/2026
AULT MILTON C III	COMPRA	+2,000	$1.03	04/14/2026	08/31/2026
AULT MILTON C III	COMPRA	+7,500	Not reported	07/31/2026	08/04/2026
Hyperscale Data, Inc.	COMPRA	+7,500	Not reported	07/31/2026	08/04/2026
Katzoff David J	COMPRA	+300,000	$2.33	04/17/2026	08/04/2026
Jackman Stephan	COMPRA	+450,000	$2.33	04/17/2026	08/04/2026
GUSTAFSON MARK	COMPRA	+60,000	$2.33	04/17/2026	08/04/2026
Oram Jeffrey	COMPRA	+60,000	$2.33	04/17/2026	08/04/2026
Horne William B.	COMPRA	+60,000	$2.33	04/17/2026	08/04/2026
AULT MILTON C III	COMPRA	+100,000	$2.33	04/17/2026	08/04/2026
Nisser Henry Carl	COMPRA	+60,000	$2.33	04/17/2026	08/04/2026
Hyperscale Data, Inc.	OTRO	+1,111	$108.00	10/30/2024	08/04/2026
Hyperscale Data, Inc.	OTRO	+988	$4050.00	04/26/2022	08/04/2026
AULT MILTON C III	COMPRA	+108,388	$1.00	04/14/2026	04/16/2026
AULT MILTON C III	VENTA	-1,851	$2.07	12/23/2025	12/30/2025
Horne William B.	VENTA	-3,333	$2.12	12/19/2025	12/23/2025
McGrath Lynne Fahey	VENTA	-30	$2.29	10/23/2025	10/24/2025
AULT MILTON C III	VENTA	-20,397	$2.32	10/09/2025	10/10/2025
AULT MILTON C III	VENTA	—	$2.32	10/08/2025	10/10/2025
AULT MILTON C III	VENTA	-101,394	$2.44	10/08/2025	10/10/2025

Sobre la compañía

Alzamend Neuro Inc

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Fuente - Link

Competidores

ACXP ADIL APRE BCDA CDIO CELZ HCWB KPRX NRSN PHIO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?

Alzamend Neuro (ALZN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial ATLANTA, Aug. 20, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience ("SfN"), to be held November 14–18, 2026 in Washington, DC. The abstract, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," will be presented as a poster in the Neuropsychiatric Disorders session (Session PSTR337) on Wednesday, November 18, 2026, from 8:00 a.m.

PRNewsWire

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects ATLANTA, Aug. 18, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting pharmacokinetic imaging data for AL001, Alzamend's novel organic lithium salt, has been accepted for oral presentation at the International Society for Magnetic Resonance in Medicine ("ISMRM") Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held from September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain. The abstract, titled "Pharmacokinetics Imaging of Lithium at 7T – Results from a Phase 1/2A Clinical Trial with a Novel Organic Lithium Salt" (Abstract #00047), was selected following a competitive review by the workshop's organizing committee and will be presented in the "Proffered Papers" oral session on Tuesday, September 29, 2026 at 1:35 PM local time.

PRNewsWire

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA, Aug. 4, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that it has entered into a Securities Purchase Agreement (the "Agreement") with Ault Lending, LLC ("Ault Lending"), pursuant to which Ault Lending has agreed to purchase up to $25,000,000 of the Company's newly designated Series D Convertible Preferred Stock (the "Preferred Shares"), and closed on the initial tranche in the amount of $7.5 million. Under the terms of the Agreement, Ault Lending agreed to purchase up to 25,000 Preferred Shares at a purchase price of $1,000 per share, for an aggregate purchase price of $25,000,000, with each Preferred Share having a stated value of $1,050.

PRNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-03-11	-0.53	-0.58	-0.05
2025-12-09	-0.83	-0.3	0.53
2025-09-10	-3.69	-1.28	2.41
2025-03-10	-2.61	-1.71	0.9
2024-12-11	-21.42	-3.6	17.82
2024-09-11	-2.38	-11.25	-8.87
2024-07-30	-2.75	-13.35	-10.6
2024-03-25	-0.32	-34.2	-33.88
2023-12-15	-0.67	39.6	40.27
2023-09-13	-47.23073	-53.98	-6.74927
2023-07-27	-30.36076	-40.48	-10.11924
2023-03-15	-0.04	-0.06	-0.02